Last reviewed · How we verify
SH-1028 tablets
SH-1028 tablets are a small molecule drug that targets the molecular target.
SH-1028 tablets are a small molecule drug that targets the molecular target. Used for Unknown.
At a glance
| Generic name | SH-1028 tablets |
|---|---|
| Sponsor | Nanjing Sanhome Pharmaceutical, Co., Ltd. |
| Drug class | Small molecule |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Unknown |
| Phase | Phase 3 |
Mechanism of action
SH-1028 tablets work by binding to the molecular target, which results in the desired therapeutic effect.
Approved indications
- Unknown
Common side effects
- Unknown
Key clinical trials
- SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations (PHASE3)
- The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028 (PHASE1)
- A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (PHASE3)
- Pharmacokinetic Study of SH-1028 Tablets in Healthy Subjects Under Fasting and Fed Conditions (PHASE1)
- Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer (PHASE1)
- Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |